NCT02430194View on ClinicalTrials.gov

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 18, 2017

Study Completion Date

June 15, 2017

Conditions
Chronic Hepatitis D Infection
Interventions
DRUG

lonafarnib

antiviral farnesyl transferase inhibitor

DRUG

ritonavir

CYP 3A4 inhibitor, lonafarnib booster

DRUG

Pegylated interferon-alfa-2a

immunomodulator

Trial Locations (1)

Unknown

Ankara University Medical School, Ankara

Sponsors
All Listed Sponsors
collaborator

Ankara University

OTHER

lead

Eiger BioPharmaceuticals

INDUSTRY

NCT02430194 - Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) | Biotech Hunter | Biotech Hunter